Introduction to the talks by Prof Gavin Giovanonni
PART 1 Introduction and Synopsis
PART 2 – Introduction (ctd) Can we Cure or Prevent MS?
An introduction to the Immunology of MS – Ute Meier
PART 1 History of Autoimmunity
PART 2 Introduction to the immune system
PART 3 A word about “mimicry” and Epstein-Barr Viruses
PART 4 Natural Killer (NK) cells and Future Research
Understanding the Pathology of MS – Sandra Amor
PART 1 Introduction to cell types in the brain: goodies and baddies.
PART 2 How do we protect nerve cells – looking at lesions – what do we see?
PART 3 – How our research fits into the equation
PART4 The Role of Macrophage Activation on Lesion Formation
MRI and MS – Klaus Schmierer
PART 1 What is MS – epidemiology and what is MRI ?
PART 2 Why is MRI useful in people with MS?
PART 3 What are the limitations of MRI and how does it help us understand and monitor MS?
PART 4 How can we overcome these limitations and what comes next?
MS and CCSVI – coming soon, awaiting formal publication of new results.
PART 1 What is the theory behind CCSVI, and how it differs from other theories of MS etiology.
PART 2 A summary of the published findings.
PART 3 Findings of a second group’s attempt to replicate the research, and what is the impact of a highly publicized trial on public perception of the evidence?
A Model of MS – David Baker
PART 1 Why safe drug development requires the use of animal models
PART 2 What MS drugs would we be using if no animal models were used?
PART 3 How do we create a good model of MS?
PART 4 The time scale of new drug development and recent developments in MS drugs
Neutralising Antibodies to IFN – Rachel Farrell
PART 1. What is interferon and how does it work in MS?
PART 2. What are neutralizing antibodies, who gets them?
PART 3. How our research is being used to help patients in the clinic.
Nataluzimab and PML – Ben Turner
Part 1. PML incidence with Natalizumab teatment, Tysabri, and what causes it (JC Virus)
PART 2. Looking for JC Virus DNA – is incidence related to duration or exposure of patients to Tysabri?
PART 3 The pathophysiology of JC Virus, PML and Natiluzimab (Tysabri)
PART 4 The Good News – The effects of Tysabri are reversible in MS patients.
Emerging Oral Therapies for MS – Giles Elrington
PART 1 – Understanding data and clinical trials
PART 2 –BG12, Laquinomod, Teriflunomide
PART 3 – Cladribine
PART 4 – Cladribine (ctd)
PART 5 – Fingolimod
PART 6 – Is It Safe?
Stem cell therapies in MS – Yuti Chernajovsky
PART 1 What are stem cells
PART 2 – Where do we get stem cells from?
PART 3 What can stem cells do for ms therapy?
PART 4 So what are the problems with stem cells ?
PART 5 inflammation is a necessary process
PART 6 Our Research –inflammation resistant stem cells and site specific biological drug delivery systems
Neuroprotection in MS Sarah Al –izki
PART 1 Neuroprotection
PART 2 The role of sodium channel blocking drugs
Sam Jackson – Remyelination in MS.
PART 1 Introduction
PART 2 Myelination
PART 3 Remyelination
PART 4 Our research – making “mini brains”
Wellness and Rehabilitation in MS – Melinda Martin
PART 1 The Concept of Wellness in MS
PART 2 The Effect of Fatigue in MS
Monitoring MS – Ruth Dobson
PART 1. How We Monitor MS
PART 2 Is There a Need for Change?
Preventing MS – Sreeram Ramagopalan
PART 1. Preventing MS
PART 2. Why sunlight and Vitamin D could be key factors